PeptideStack
5.2kquestions
20kanswers
220users

How many freeze-thaw cycles will oral semaglutide at 1 mg/mL tolerate?

Asked 20 Feb 2025Modified 13 months agoViewed 22k times
20

The specifics, since they change the answer: oral semaglutide · 1 mg/mL.

I want a method I can write down and repeat, not a rule of thumb.

I would rather over-engineer this than discover a problem later, within reason.

Which parts of this are load-bearing and which parts are habit?

freeze-thaw
freeze-thaw

What repeated freezing does to a peptide in solution: ice-crystal shear at the growing front, freeze-concentration of solutes, pH shifts as buffer…

57 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
shareeditfollowflag
TW
askedtare_weight60k14820 Feb 2025

5 Answers

Accepted answer first, then by votes
86

Accepted answer

Nobody has published a cycle count, and at 1 mg/mL the concentration tells you what a wrong guess costs: a 0.1 mL aliquot holds 0.1 mg and every microlitre is 1 µg. Damage from freezing is not gradual attrition — it is concentrated at the phase transitions, where ice excludes solute and the unfrozen fraction climbs well above 1 mg/mL for as long as the transition lasts. Two slow cycles can therefore do more than four fast ones, which is why a cycle count is the wrong unit in the first place. The way to make the number one is to make it one: split at reconstitution into single-draw aliquots, label each with 1 mg/mL and the date, and never thaw a container you will refreeze.

The short version: aliquot before freezing, thaw slowly, never refreeze a thawed aliquot, and count your cycles.

Let a frozen vial reach room temperature before opening it. Opening a cold vial in humid air condenses water into the cake, which raises residual moisture and undoes what lyophilisation achieved.

Buffer salts crystallise at different points during freezing. Sodium phosphate is the classic example: the dibasic form crystallises first and the pH of the residual liquid falls by several units. That pH excursion is the real damage in many cases.

Cryoconcentration of solutes at the ice front is a well-documented mechanism in freeze-thaw damage to proteins and peptides.

The caveat is that aggregation is invisible in a clear solution below the threshold where it becomes visible.

Aliquot before the first freeze. That is the whole answer.

edited 28 Mar 2025 by marta_okonkwo — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
MO
answered · acceptedmarta_okonkwo190k25826 Feb 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
73

Answering this needs to know whether the material is dry or in solution, since a dry powder is largely indifferent to a temperature cycle.

Never refreeze a thawed aliquot. The whole point of aliquoting is that the aliquot is single-use, and refreezing it discards the benefit.

Thaw slowly at room temperature or in the refrigerator rather than in warm water. Rapid warming creates local thermal and concentration gradients that promote aggregation.

Aliquoting to eliminate repeated cycles is standard laboratory practice for exactly this reason.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Thaw slowly and never refreeze an aliquot.

shareimprove this answerflag
MO
answeredmarta_okonkwo190k25810 Mar 2025
36

The relevant physics is ice-front concentration: as water crystallises, everything dissolved is concentrated into the shrinking liquid phase, including buffer salts.

During freezing, solutes are excluded from the ice lattice and concentrate into the residual liquid. Local concentrations can rise many-fold, which promotes aggregation independently of temperature.

To be exact about it, a dry lyophilised powder is much less affected by a temperature cycle because there is no liquid phase for anything to concentrate into. Condensation on a cold vial opened warm is the real risk there.

Aliquoting itself is a handling step and introduces its own contamination opportunity.

Dry powder tolerates cycles far better than solution does.

shareimprove this answerflag
TW
answeredtare_weight60k14815 Jun 2025
29

On the detail: buffer components crystallise at different rates during freezing, which shifts pH locally by a surprising amount.

The mitigation is aliquoting. Divide the reconstituted solution into single-use volumes before the first freeze, and each aliquot then experiences exactly one cycle.

Count cycles, not degrees. The cycle is the damaging event.

shareimprove this answerflag
DL
answeredDr_Otto_Lindqvist72k584 Jun 2025
2Thank you — this is the answer I was looking for. – RP_C18 2 months ago
3The desiccant point is under-appreciated and costs nothing to act on. – meniscus_film 4 months ago
add a comment
23

Mechanically, thawing at room temperature rather than in warm water reduces the interfacial stress.

Count cycles rather than worrying about degrees. Minus twenty and minus eighty differ far less than one cycle and five do.

Condensation onto cold lyophilised material on opening is a recognised handling error and is the basis for the equilibrate-before-opening rule.

Let a frozen vial reach room temperature before opening, or you condense water into it.

shareimprove this answerflag
EV
answeredekaterina_volk21k2823 Apr 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.